Use of Sacubitril/Valsartan Will Improve The Management of Hypertension In China Perspectives A There are approximately 245 million adults with hypertension in China. According to the most recent China Hypertension Survey conducted by the National Center for Cardiovascular Disease from October 2012 to December 2015 1, hypertension awareness, treatment and control rates were 51.6%, 45.8% and 15.3%, respectively. Because of low awareness, at their initial contact with a doctor, many Chinese hypertensive patients often already show serious target organ damage or even overt cardiovascular disease, such as left ventricular hypertrophy (LVH), renal dysfunction and so on. That explains why many Chinese hypertensive patients are at high cardiovascular risk. Given the increasing longevity and prevalence of hypertension in China, there is a huge challenge in the management of hypertension in this populous country.